Christopher Missling | President and Chief Executive Officer |
Sandra Boenisch | Principal Financial Officer & Treasurer |
Charles Duncan | Cantor Fitzgerald |
Jeffrey Cohen | Ladenburg Thalmann |
Raghuram Selvaraju | H.C. Wainwright |
Tom Bishop | BI Research |
[Abrupt Start] | |
… recommendation for each of the three studies. The DSMB recommendation is to continue the studies without modifications. This is very good news and indicates we are on the right path with all these studies. | |
As a reminder of our clinical strategy is to clearly differentiate from other biopharma companies and clinical studies in CNS | Anavex is continuing to pioneer the approach of big data - including all mix [ph] in clinical trials to leverage the relevance of phenotypic and genotypic precision medicine analysis of whole genome sequencing and gene expression data in drug development. And in particular - the potential to identify patients' genetic variants and gene expression changes that may predict increased chances of success of Rett syndrome - Parkinson's disease - and Alzheimer's disease treatments. |
And now I would like to direct the call to Sandra Boenisch | principal financial officer of Anavex - for a brief financial summary of the recent reported quarter. |
Thank you, Christopher and good afternoon, everyone.
We continue to apply fiscally responsible management of cash utilization with moderate increases within budget. We reported a net loss of $8.2 million for the quarter or $0.12 per share as compared to $7.2 million also $0.12 per share in the comparable quarter of last year. Research and development expenses were $6.7 million for the quarter compared to $6.1 million for the comparable quarter of fiscal 2020. The increase is primarily attributable to the continued advancement of our ongoing clinical trials.